Quizartinib (AC220): Selective FLT3 Inhibitor for Acute Myeloid Leukemia Research

Executive Summary: Quizartinib (AC220) is a selective, second-generation inhibitor of FLT3 with an IC₅₀ of 1.1 nM against FLT3-ITD, supporting its use in acute myeloid leukemia (AML) models (APExBIO). It exhibits at least ten-fold selectivity over other kinases such as PDGFRα and KIT, enabling precise targeting of FLT3-driven signaling. Cellular and in vivo studies confirm robust inhibition of FLT3 autophosphorylation and extension of survival in mouse xenograft models. Pharmacokinetic profiling reveals oral bioavailability with a C_max of 3.8 μM within 2 hours post-dose. Resistance mutations in FLT3 can emerge, highlighting the need for ongoing research into FLT3 signaling and targeted therapy (Shin et al., 2023).

Biological Rationale

FLT3 (FMS-like tyrosine kinase 3) is a receptor tyrosine kinase expressed in hematopoietic progenitor cells. Mutations in FLT3, especially internal tandem duplications (ITD), occur in approximately 30% of AML cases and are linked to poor prognosis and higher relapse rates (Shin et al., 2023). Aberrant FLT3 signaling activates downstream pathways, notably JAK-STAT and PI3K-AKT, promoting cell proliferation and survival. Drug resistance to BCR-ABL1 inhibitors in blast phase chronic myeloid leukemia (BP-CML) is often mediated by upregulation of FLT3 signaling, underscoring its importance as a therapeutic target (Transforming FLT3-Targeted Research). Quizartinib (AC220) enables precise dissection of these pathways, advancing AML research beyond conventional chemotherapeutics.

Mechanism of Action of Quizartinib (AC220)

Quizartinib (AC220) is a highly potent, ATP-competitive inhibitor of FLT3. It binds to the FLT3 kinase domain, inhibiting autophosphorylation and consequently blocking downstream signaling. The compound acts on both FLT3-ITD (IC₅₀ = 1.1 nM) and wild-type FLT3 (IC₅₀ = 4.2 nM) (APExBIO product page). Its selectivity profile shows at least ten-fold less activity against kinases such as PDGFRα, PDGFRβ, KIT, RET, and CSF-1R. By halting FLT3-driven signal transduction, Quizartinib effectively suppresses proliferation and induces apoptosis in AML cell lines like MV4-11 and RS4;11. In mouse xenograft models, oral administration at doses as low as 1 mg/kg results in significant FLT3 inhibition, tumor regression, and prolonged survival. The primary mechanism involves inhibition of FLT3 autophosphorylation, a critical step for leukemia cell maintenance and resistance (Shin et al., 2023).

Evidence & Benchmarks

• Quizartinib inhibits FLT3-ITD with an IC₅₀ of 1.1 nM and FLT3-WT at 4.2 nM in biochemical assays (APExBIO).
• It demonstrates >10-fold selectivity for FLT3 over PDGFRα, PDGFRβ, KIT, RET, and CSF-1R (APExBIO).
• Quizartinib blocks FLT3 autophosphorylation in MV4-11 and RS4;11 AML cell lines at nanomolar concentrations (Quizartinib: Selective FLT3 Inhibitor for AML Res...).
• In mouse xenograft models, oral dosing at 1 mg/kg achieves significant FLT3 inhibition and tumor regression (Shin et al., 2023).
• Pharmacokinetic studies show a C_max of 3.8 μM reached within 2 hours (oral administration) (APExBIO).
• FLT3 signaling is a central driver of acquired drug resistance in BP-CML, with Quizartinib overcoming resistance in preclinical models (Shin et al., 2023).
• Quizartinib is soluble at ≥28.03 mg/mL in DMSO but insoluble in ethanol and water (APExBIO).

Applications, Limits & Misconceptions

Quizartinib is primarily employed in academic and translational research for:

• FLT3 autophosphorylation inhibition assays
• Modeling FLT3-driven leukemogenesis in AML and BP-CML (Advanced Strategies for Modeling and...)
• Dissecting resistance mechanisms in kinase inhibitor studies
• In vivo efficacy testing in mouse xenograft models
• Pharmacokinetic and pharmacodynamic profiling for novel inhibitor development

This article extends previous summaries (Quizartinib: A Selective FLT3 Inhibitor for AML R...) by providing updated mechanistic insights and clarifying selectivity and workflow parameters.

Common Pitfalls or Misconceptions

• Quizartinib is not effective against all resistance mutations in FLT3; certain gatekeeper mutations confer resistance (Shin et al., 2023).
• It is not recommended for diagnostic or therapeutic use in humans; intended strictly for research (APExBIO).
• Solubility limitations: insoluble in ethanol and water restrict buffer compatibility.
• Long-term storage of solutions is not advised due to compound instability; use immediately after preparation.
• Quizartinib does not inhibit BCR-ABL1 kinase and should not be used as a substitute for BCR-ABL1-targeted therapies.

Workflow Integration & Parameters

Quizartinib (AC220) is supplied as a solid by APExBIO (SKU: A5793) and should be stored at -20°C. It is dissolved in DMSO at concentrations ≥28.03 mg/mL for in vitro use. For cellular assays, nanomolar working concentrations (e.g., 1–10 nM) are typical. In vivo, oral dosing at 1–10 mg/kg has been validated in FLT3-dependent mouse xenograft models. Pharmacokinetic monitoring suggests a C_max near 3.8 μM 2 hours post-dose. Solutions should be prepared fresh and not stored long-term. For robust data on FLT3 inhibition or resistance assays, controls should include vehicle and non-FLT3-mutant lines. For more detailed protocol integration, see the official Quizartinib (AC220) product page or consult the comparative Quizartinib: Selective FLT3 Inhibitor for AML Res... which focuses on autophosphorylation inhibition assays.

Conclusion & Outlook

Quizartinib (AC220) has emerged as a benchmark tool compound for selective FLT3 inhibition in AML and BP-CML research. Its nanomolar potency, selectivity, and in vivo efficacy support its integration into translational workflows. Ongoing studies are redefining the role of FLT3 signaling in drug resistance, with Quizartinib providing both mechanistic clarity and a platform for next-generation inhibitor discovery. For researchers, the A5793 Quizartinib kit from APExBIO offers validated performance and detailed guidance for AML model systems.